Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dan, do you know if TDA lets one trade spreads? I've been selling and then rebuying later options to roll forward; this seems more logical and likely less transactional friction (or cost, lol).
The AHA Science News site has a link for REDUCE-IT Clinical Trials Details.
Details are currently embargoed, but the embargo will be lifted when the presentation begins tomorrow. Below are the specific links for the abstract, presentation slides, and discussant slides. There is also a placeholder, but not hyperlink, for the NEJM article, so hoping it is published contemporaneously online. I suspect the NEJM doesn't allow anyone to have control of when a hyperlink goes live, thus no link at present.
Abstract for REDUCE-IT
Presentation Slides (PDF)
Discussant Slides (PDF)
Published in NEJM: I'll update this tomorrow, if it goes live.
MP, I'm sure someone will be posting; several have mentioned that. In addition, the Readout says they'll tweet as soon as news is released. I believe the link below will connect with their news stream for tomorrow.
The Readout
The supply issue is not an actual issue... Would be nice if it was...
eboomer, thanks for sharing your perspective on potential buyout levels and issues. I could see why several of the pharmas might want to point to the US market for valuation, and have a reluctance to go over $30B as their top-end offer. I think that's too low, and expect Bakers may agree, which is more important. Would a scenario make sense where Amarin sells off its US/N American market to BP, but retains the rest of the world for GIA or other, separate deals?
I could see that being sen as a positive bu Euro regulators, for example, while also being a means to achieve a fairer valuation for shareholders and management.
Price isn't moving much, but my calls are moving nicely at the end here...
That's a great movie. Albert Brooks is a genius.
$22.25
Yeah; love that one. Maybe we can recycle that next year for V after some post hoc analysis...
LMAO. Missed that; pretty damn funny.
Sounds like a scared short...
Pyrr, gotta say this puzzles me. The risk/reward for a large short here doesn't measure up to the calculus I thought you used: going for the singles, happily collecting them steadily while others aimed for the fences and missed more often than not, but got to boast about the occasional big wins. Honestly, it's an approach I tend to use; AMRN is my exception to the rule, due to some extraordinary aspects to it.
At this point it feels like it's become personal to you, to the point of trying to prove to the folks on this board that you are right and they (we) are wrong. Emotional investing is a dangerous place to be. Even if you are proved correct--something I see as a very slim possibility, but there is always some risk--I doubt you'd find the experience as satisfying as you think it would be as a prospect.
GLTY.
I worry about him being involved with REDUCE-IT, given that in his oral history there he said he was the kiss of death, in that the trials he'd been involved in showed harm, rather than the predicted efficacy...
Hopefully this is the trial that changed that record...
Thanks, Sam. Guessing the Gen Lovaza is up because many docs do not yet discern the difference between L and V. That will start to change in a big way tomorrow...
Bond markets and banks are closed. Usually equities markets follow their schedule, but this is an exception.
Not overly surprised here. We've dealt with skepticism for over five years, and get that we are ahead of the curve, thanks to some pretty amazing posters, in terms of understanding of the method of action and implications of Vascepa as a treatment for systemic inflammation, including CVD issues.
In my opinion, shared I think by many others here--smarter than me; I've benefited from there sharing--the medical community and investment community will have a greater grasp of what V can do after this weekend's presentations at the AHA conference in Chicago. Amarin gave a glimpse on Sept 24th, bu only explicitly provided topline data. Skepticism runs deep regarding V working, though, so many are hedging until they see the Secondary Endpoints (SEs) reported out, which happens 11/10 around 2:30.
Lol, you are a charmer, aren't you? Come to the board asking for info that you ought to simply look up or read through a few posts to find out. Then you cop an attitude because you ask troll-like questions, and folks don't simply lay out the long case for you.
You need to grow up a little, or you'll never be able to move out of your folks' basement.
Dr. Bhatt's most recet original tweet is from 11/4, announcing a CME he and Dr. Ballantyne run on PSCK9 inhibitors. Quite a few more recent retweets, basically getting the work out about a number of folks' takes, programs and interests in the AHA conference. Don't see anything to read into any of these. Maybe you could be less cryptic?
Maz, until we get into triple digits, I won't make the millionaires club, but thankful nonetheless for where I am heading thanks to AMRN. I'd join such an effort...
Tasty, where does "the Miracle in the Meadowlands" figure in your ranking of miracles?
We survived St. Crispin's Day--10/25--quite nicely. It is however, the date on which the Chinese Army retook Nanking in 1911 (be glad you weren't there), as well as the anniversary of the founding of the US Marine Corps (first edition, the Continental Marines in 1775, the USMC in 1801). Semper fi--always faithful--is the USMC motto, but seems apt for many on this board with regard to AMRN, too.